carecentrix

Provider Newsflash March 5, 2020

FDA RECALL

Purpose of this communication:

We are writing to inform you that effective immediately, the FDA has issued notice of a voluntary recall by Hikma Pharmaceuticals USA, Inc. of 8 lots of their Ketorolac Tromethamine Injection USP 30mg/ml, 1 ml fill/2ml vials to the medical facility and retail levels due to the presence of small visible particulate matters of a gelatinous/oily nature that appear black in some of the recalled lots. This is an extension of Hikma's previous voluntary recall of this product to the direct consumer level issued on December 23, 2019.

What do I need to do?

- Please review the following recall notice:
- https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hikma-pharmaceuticals-usa-inc-extends-voluntary-nationwide-recall-ketorolac-tromethamine-injection?utm_campaign=Hikma%20Pharmaceuticals%20USA%20Inc.%20Extends%20Voluntary%20Nationwide%20Recall%20of%20Ketorolac%20Tromethamine&utm_medium=email&utm_source=Eloqua
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by:
    - Faxing information– To: 919-792-6718 Attn: Quality Department

Thank you for your prompt attention and cooperation in this matter.